Gennex Laboratories Ltd - Stock Valuation and Financial Performance

BSE: 531739 | NSE: | Pharmaceuticals & Drugs | Small Cap

Gennex Lab Share Price

15.85 0.26 1.67%
as on 28-Mar'24 14:58

DeciZen - make an informed investing decision on Gennex Lab

Overall Rating
M-Cap below 500cr. High Risk from low Liquidity Bole Toh

1. Quality

2. Valuation

Overvalued

3. Price Trend

Gennex Laboratories stock performance -

mw4me loader
P/E Ratio (SA):
37.42
Market Cap:
357 Cr.
52-wk low:
5.3
52-wk high:
21.9

Is Gennex Laboratories Ltd an attractive stock to invest in?

1. Is Gennex Laboratories Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Gennex Laboratories Ltd is a below average quality company.

2. Is Gennex Laboratories Ltd undervalued or overvalued?

The key valuation ratios of Gennex Laboratories Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is Gennex Laboratories Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Gennex Laboratories Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Gennex Lab:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Gennex Laboratories Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
ROCE % 1.2%3.3%9%9.9%3.9%7.6%5.5%10.4%8.4%7.5%-
Value Creation
Index
-0.9-0.8-0.4-0.3-0.7-0.5-0.6-0.3-0.4-0.5-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 3531.938.641.943.855.855.659.761.265.164
Sales YoY Gr.--8.8%20.9%8.7%4.5%27.5%-0.3%7.3%2.6%6.4%-
Adj EPS 00.10.20.20.10.20.10.30.30.20.4
YoY Gr.-400%260%16.7%-71.4%183.3%-29.4%158.3%-9.7%-14.3%-
BVPS (₹) 1.91.92.12.32.42.62.733.34.57
Adj Net
Profit
0.10.62.42.70.92.21.64.13.74.210
Cash Flow from Ops. 0.50.23.4-0.13.21.9-1.7-1.46.6-14.5-
Debt/CF from Ops. 6.518.60.7-36.20.82.4-3-5.11.5-0.2-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 7.1%8.3%5.4%6.4%
Adj EPS 42.4%32%26%-14.3%
BVPS9.9%13.1%18.1%34%
Share Price 34% 40.2% 63% 190.8%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
Return on
Equity %
0.42.58.79.22.76.74.710.78.76.97.3
Op. Profit
Mgn %
4.76.310.910.95.27.25.8118.8720.3
Net Profit
Mgn %
0.326.16.5242.96.866.515.1
Debt to
Equity
0.10.20.10.10.10.10.10.20.20-
Working Cap
Days
147181160185203161184204213249217
Cash Conv.
Cycle
-13-1261021533254370168

Recent Performance Summary

Net Profit is growing at healthy rate in last 3 years 25.99%

Return on Equity has declined versus last 3 years average to 7.30%

Sales growth has been subdued in last 3 years 5.39%

Sales growth is not so good in last 4 quarters at -2.81%

Latest Financials - Gennex Laboratories Ltd.

Standalone Consolidated
TTM EPS (₹) 0.4 0.3
TTM Sales (₹ Cr.) 63.6 65.6
BVPS (₹.) 7 7.1
Reserves (₹ Cr.) 138 140
P/BV 2.22 2.19
PE 37.42 57.64
From the Market
52 Week Low / High (₹) 5.33 / 21.89
All Time Low / High (₹) 0.22 / 21.89
Market Cap (₹ Cr.) 357
Equity (₹ Cr.) 22.9
Face Value (₹) 1
Industry PE 47.8

Management X-Ray of Gennex Lab:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.008.078.078.078.843.463.4634.1734.140.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Gennex Lab

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Sales35323942445656606165
Operating Expenses 33303437425252535661
Manufacturing Costs4455688668
Material Costs23202324273334363840
Employee Cost 3345667778
Other Costs 3234454445
Operating Profit 2245243755
Operating Profit Margin (%) 4.6%6.3%10.9%10.8%5.0%7.2%5.8%11.0%8.8%7.0%
Other Income 0000111113
Interest 0011111111
Depreciation 1111111111
Exceptional Items 0000000000
Profit Before Tax 1133133556
Tax 0010111111
Profit After Tax 0123122445
PAT Margin (%) 0.6%2.1%6.1%6.5%1.9%4.0%3.3%6.8%6.4%7.0%
Adjusted EPS (₹)0.00.10.20.20.10.20.10.30.30.3
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23

Equity and Liabilities

Shareholders Fund 25262831323436404479
Share Capital 13131313131313131318
Reserves 13131618192123273161
Minority Interest0000000000
Debt34243557102
Long Term Debt1000000001
Short Term Debt33242557101
Trade Payables87791288686
Others Liabilities 3345458668
Total Liabilities 40394249505257596896

Fixed Assets

Gross Block26262728293030303133
Accumulated Depreciation10121212131415161717
Net Fixed Assets16151516161615141415
CWIP 0000000000
Investments 7777777778
Inventories21332575815
Trade Receivables56710101068119
Cash Equivalents 01111311814
Others Assets99813141021242034
Total Assets 40394249505257596896

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Cash Flow From Operating Activity 003032-2-17-14
PBT 1133133556
Adjustment 111222223-1
Changes in Working Capital -1-2-1-41-3-6-7-0-20
Tax Paid 000-1-100-2-10
Cash Flow From Investing Activity -10-1-1-1-100-1-1
Capex -10-1-1-1-1000-2
Net Investments 000000000-1
Others 00000000-13
Cash Flow From Financing Activity 00-21-2102221
Net Proceeds from Shares 00000000030
Net Proceeds from Borrowing 0000000001
Interest Paid 00-1-1-1-1-1-1-1-1
Dividend Paid 0000000000
Others 11-12-22023-9
Net Cash Flow 000002-2076
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Ratios
ROE (%)0.822.578.699.142.676.755.3210.669.357.43
ROCE (%)3.634.5711.7811.616.3110.498.3213.1811.7810.7
Asset Turnover Ratio0.950.8510.960.951.171.11.11.030.87
PAT to CFO Conversion(x)NAN01.5031-1-0.251.75-2.8
Working Capital Days
Receivable Days45606072806351405352
Inventory Days19171924202339363658
Payable Days10712911112614811388726665

Gennex Laboratories Ltd Stock News

Gennex Laboratories Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Gennex Lab on 28-Mar-2024 14:58 is ₹15.85.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 28-Mar-2024 14:58 the market cap of Gennex Lab stood at ₹357.0.
The latest P/E ratio of Gennex Lab as of 28-Mar-2024 14:58 is 37.42.
The latest P/B ratio of Gennex Lab as of 28-Mar-2024 14:58 is 2.22.
The 52-week high of Gennex Lab is ₹21.89 and the 52-week low is ₹5.33.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Gennex Lab is ₹63.62 ( Cr.) .

About Gennex Laboratories Ltd

Gennex Laboratories (formerly Prudential Pharmaceuticals) is a public limited company established in the year 1995 and has been engaged in the manufacturing of bulk drugs and intermediates. The company started as one of the leading manufacturer and exporter of bulk drugs and intermediates. Quality is the strength of the company and major part of its finished products are exported to various countries viz. Germany, United Kingdom, Spain, Singapore, Canada, Switzerland, Iran, Bangladesh, Pakistan and other major countries. Gennex Laboratories has diversified its activities to biotech products in order to have better prospects and opportunities for the company for expanding its bussiness activities and to meet the marketing requirements.

The company had commenced its commercial operations of Guaifenesin in November, 1995 and in a span of about one and half years, it was able to capture about 70% of the domestic market mainly due to the impeccable quality, aggressive marketing strategies, cost effective manufacturing and efficient distribution cum market penetration. It has also established itself fairly well in the export market and recognized well by many end-users and trading giants of international market.

The company has catered to countries like USA, Mexico, Spain and Germany and the quality has been accepted and appreciated extremely well with all the customers. Several customers have evinced interest on long-term tie-ups. Slowly but surely, the company is constantly expanding its reach to USA and European markets and it has been receiving very encouraging enquiries from prospective customers based on quality recommendations by existing customers. The company’s headquarters is situated in the heart of the city and the factory is situated at Survey No 133, IDA Bollaram, Jinnaram Mandal, Medak District-502 325, Andhra Pradesh, India. The factory occupies a total land area of 8,000 square meters. The total building floor space is1,945 square meters. The storage space is 500 square meters. The central lab has a floor space of 225 square meters.

Products of the company:

  • Guaiphenesin
  • Methocarbamol
  • Fluconazole
  • Phenazopyridine

Certification:

  • Gennex Laboratories is an ISO 9001: 2008 approved company and obtained GMP Certification from the Central Drug Authority.
  • The company is also planning for ISO 14001: 2002 certification and OHSHAS 18000 to ensure its products are more widely accepted in the international market.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.